Wockhardt loss narrows to Rs 86 crore in Q3
New Delhi: Pharmaceuticals firm Wockhardt Ltd has reported narrowing of consolidated net loss to Rs 86 crore for the third quarter ended December 31, 2023.The company had incurred a loss of Rs 102 crore in the third quarter last fiscal, Wockhardt Ltd said in a regulatory filing.Revenue from operations during the quarter under review stood at Rs 701 crore as compared to Rs 699 crore in...
New Delhi: Pharmaceuticals firm Wockhardt Ltd has reported narrowing of consolidated net loss to Rs 86 crore for the third quarter ended December 31, 2023.
Revenue from operations during the quarter under review stood at Rs 701 crore as compared to Rs 699 crore in the year-ago period, the company said.
Total expenses were lower at Rs 796 crore as against Rs 803 crore in the same period last fiscal.
Read also: Wockhardt Gets CDSCO Panel Nod To study combination of cefepime and zidebactam
Headquartered in Mumbai, Wockhardt is an Indian pharmaceutical and biotechnology company. The Company produces biopharmaceuticals, nutrition products, formulations, vaccines and active pharmaceutical ingredients (APIs). Its manufacturing plants are located in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France.
Original news source: https://www.ptinews.com/story/business/wockhardt-q3-loss-narrows-to-rs-86-cr/1290002
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd